Study Overview

Investigation Team

Dr Josep Mallolas Masferrer

Dr María Martínez-Rebollar

Hospital Clínic-Barcelona
Barcelona
Spain

Co-investigators
José Luis Blanco Arevalo
Montserrat Laguno Centeno
Lorna Leal
Jordi Blanch
Amparo Tricas
Ana Rodríguez

Proposed finish date
1 March 2021

HIV Care Continuum stages covered (3)

Currently in Spain, the majority of new HIV infections, new HCV infections and other sexually transmitted infections (STI), occur in the group of men who have sex with men (MSM). 

At the same time, an increase in the use of substances in sexualized context to extend and enhance sexual intercourse, has been described in recent years, mainly in MSM, and related to sexual risk behaviors. We believe that identifying this high risk population, offering  HIV, HCV and STIs tests and early treatment, will impact in reducing the incidence, bringing us closer of the first two 90-90-90 objectives of UNAIDS.  

References
1. Glen P. Davis, Hilary L. Surratt, Frances R. Levin. Antiretroviral medication: an emergent category of prescription drug misuse Am J Addict. 2014 November; 23 (6): 519-525
2. Kramer S, Schmidt A, Berg R, Furegato M, Hospers H, Folch C, et al. Factors associated with unprotected anal sex with multiple non-steady partners in the past 12 months: results from the European Men-Who-Have-Sex-With-Men Internet Survey (EMIS 2010). BMC Public Health. 2016; 16:47

1 Primary objective

To offer diagnostic tests for HIV, HCV and other STIs in a high risk population (MSM Chemsex users) in order to make early diagnosis, treatment and monitoring of these infections in order to reduce the incidence.

2 Secondary objective

To train health care professionals (HCPs) to recognise the warning signs of ChemSex, as well as the signs and symptoms of HIV and other STIs.

3 Tertiary objective

To connect patients who engage in ChemSex with specialised treatment units.

4 Quaternary objective

To identify the prevalence of ChemSex in Barcelona and to establish the value of implementing campaigns that encourage responsible consumption of substances, thereby lowering the risks associated with these behaviours.

This pilot, prospective cohort, single center study, will run for three years. Patients will be included in the first year, with subsequent follow-up during the following two years.

A comparative study of the incidences of HIV, HCV, and STIs is planned at the start of the project, and again two years after implementation.

01.  

During the first three months, HCPs receive specialised training in identifying and treating ChemSex users. Patients who are possible candidates also receive educational pamphlets and study information. After initiating the first training, recruitment will start. 

02.  

Candidates referred will receive validated questionnaires aimed at determining their eligibility for the study, including a consumption risk assessment, STI and sexual risk behaviour assessment. Blood test to screen for HIV, HCV serology and syphilis, and multiple PCR for chlamydia and gonorrhoea in genital samples will be performed.

03. 

Follow-up blood tests and genital samples will be performed every three months. A medical and nursing clinic has been opened specifically for the care and follow-up of these patients. In each visit we will assess consumption risk and sexual risk behaviour.

04. 

All information collected will be included in a Research Electronic Data Capture database. Descriptive analysis will be performed by a statistical analysis team, using STATA Statistical Software. The prevalence of ChemSex, as well as the incidence of HIV seroconversion and the identification of new STI infections over the course of the study period, will be calculated by the investigators. These seroconversions will be characterised and associated with a risk factor. 

Conclusion

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at.

Limitations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum eget sagittis massa. Pellentesque faucibus nisi metus, eu interdum lacus hendrerit ut. Proin sed lacus ullamcorper, gravida ipsum at.